Current status and progress in gastric cancer with liver metastasis

Chinese Medical Journal

Volumn 124, Issue 3, 2011, Pages 445-456

  Liu, Jing ^a,b   Chen, Lin ^a,b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

Diagnostic imaging; Gastric cancer; Liver metastasis; Therapeutics

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GADOLINIUM; GADOXETIC ACID; IRINOTECAN; MELANOMA ANTIGEN; MELANOMA ANTIGEN A; MITOMYCIN C; SALL4 PROTEIN; SCATTER FACTOR RECEPTOR; SUPERPARAMAGNETIC IRON OXIDE; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN A; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 3;

CANCER CLASSIFICATION; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRYOABLATION; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ECHOGRAPHY; GASTRECTOMY; HUMAN; LIVER METASTASIS; LIVER RESECTION; MELANOMA ANTIGEN A10 GENE; METASTASIS RESECTION; MICROMETASTASIS; MICROWAVE THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTO ONCOGENE; PROTO ONCOGENE C MET; RADIOFREQUENCY ABLATION; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; TUMOR GENE; UNSPECIFIED SIDE EFFECT;

HUMANS; LIVER NEOPLASMS; STOMACH NEOPLASMS;

EID: 79551697790     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.03.023     Document Type: Review

References (116)

1. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis 2010; 31: 100-110.
2. Zhang SW, Lei ZL, Li GL, Zou XN, Zhao P, Chen WQ. A report of cancer incidence and mortality from 34 cancer registries in China, 2006. China Cancer (Chin) 2010; 19: 356-365.
3. Marrelli D, Roviello F, De Stefano A, Fotia G, Giliberto C, Garosi L, et al. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection. J Am Coll Surg 2004; 198: 51-58.
4. Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Seto Y, et al. Liver resection for metastatic gastric cancer: experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol 2007; 37: 836-842.
5. Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, et al. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 2007; 95: 534-539.
6. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol 2008; 19: 1146-1153.
7. Tiberio GA, Coniglio A, Marchet A, Marrelli D, Giacopuzzi S, Baiocchi L, et al. Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. Eur J Surg Oncol 2009; 35: 486-491.
8. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Naka T, Ishida K, et al. Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg 2009; 394: 647-653.
9. Hwang SE, Yang DH, Kim CY. Prognostic factors for survival in patients with hepatic recurrence after curative resection of gastric cancer. World J Surg 2009; 33: 1468-1472.
10. Thelen A, Jonas S, Benckert C, Lopez-Hanninen E, Neumann U, Rudolph B, et al. Liver resection for metastatic gastric cancer. Eur J Surg Oncol 2008; 34: 1328-1334.
11. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. 1st English ed. Tokyo: Kanehara; 1995.
12. Moriguchi S, Maehara Y, Korenaga D, Sugimachi K, Nose Y. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol 1992; 1: 341-346.
13. Kumagai K, Shimizu K, Yokoyama N, Aida S, Tanaka T, Yamagata K. Gastrointestinal cancer metastasis and lymphatic advancement. Surg Today 2010; 40: 301-306.
14. Kumagai K, Tanaka T, Yamagata K, Yokoyama N, Shimizu K. Liver metastasis in gastric cancer with particular reference to lymphatic advancement. Gastric Cancer 2001; 4: 150-155.
15. Nomura T, Kamio Y, Takasu N, Moriya T, Takeshita A, Mizutani M, et al. Intrahepatic micrometastases around liver metastases from gastric cancer. J Hepatobiliary Pancreat Surg 2009; 16: 493-501.
16. Nakanishi H, Yasui K, Ikehara Y, Yokoyama H, Munesue S, Kodera Y, et al. Establishment and characterization of three novel human gastric cancer cell lines with differentiated intestinal phenotype derived from liver metastasis. Clin Exp Metastasis 2005; 22:137-147.
17. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, et al. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol 2007; 60: 273-277.
18. Kocer B, Soran A, Kiyak G, Erdogan S, Eroglu A, Bozkurt B, et al. Prognostic significance of mucin expression in gastric carcinoma. Dig Dis Sci 2004; 49: 954-964.
19. Tajima Y, Yamazaki K, Nishino N, Morohara K, Yamazaki T, Kaetsu T, et al. Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions. Br J Cancer 2004; 91: 1342-1348.
20. Wakatsuki K, Yamada Y, Narikiyo M, Ueno M, Takayama T, Tamaki H, et al. Clinicopathological and prognostic significance of mucin phenotype in gastric cancer. J Surg Oncol 2008; 98: 124-129.
21. Makino H, Kunisaki C, Izumisawa Y, Tokuhisa M, Oshima T, Nagano Y, et al. Indication for hepatic resection in the treatment of liver metastasis from gastric cancer. Anticancer Res 2010; 30: 2367-2376.
22. Li C, Yan M, Chen J, Xiang M, Zhu ZG, Yin HR, et al. Survival benefit of non-curative gastrectomy for gastric cancer patients with synchronous distant metastasis. J Gastrointest Surg 2010; 14: 282-288.
23. Shiraishi N, Sato K, Yasuda K, Inomata M, Kitano S. Multivariate prognostic study on large gastric cancer. J Surg Oncol 2007; 96: 14-18.
24. Deng J, Liang H, Sun D, Pan Y, Wang B, Guo Y. Vascular endothelial growth factor-D is correlated with hepatic metastasis from gastric cancer after radical gastrectomy. Surgery 2009; 146: 896-905.
25. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-827.
26. Mimori K, Fukagawa T, Kosaka Y, Kita Y, Ishikawa K, Etoh T, et al. Hematogenous metastasis in gastric cancer requires isolated tumor cells and expression of vascular endothelial growth factor receptor-1. Clin Cancer Res 2008; 14: 2609-2616.
27. Shida A, Fujioka S, Kobayashi K, Ishibashi Y, Nimura H, Mitsumori N, et al. Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. Int J Clin Oncol 2006; 11: 38-43.
28. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Van de Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802-804.
29. Toschi L, Janne PA. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res 2008; 14: 5941-5946.
30. Park M, Park H, Kim WH, Cho H, Lee JH. Presence of autocrine hepatocyte growth factor-Met signaling and its role in proliferation and migration of SNU-484 gastric cancer cell line. Exp Mol Med 2005; 37: 213-219.
31. Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, An FQ, et al. c-Met expression in gastric cancer with liver metastasis. Oncology 2002; 63: 286-296.
32. Cho H, Zhang X, Jung M, Kwon W, Jung J, Jeung H, et al. C-met as a therapeutic target for metastatic potential of gastric cancer. J Clin Oncol 2010; 28 Suppl 15: e14568.
33. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994; 40: 360-369.
34. Suzuki S, Sasajima K, Sato Y, Watanabe H, Matsutani T, Iida S, et al. MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer. Br J Cancer 2008; 99: 350-356.
35. Alves PM, Levy N, Bouzourene H, Viatte S, Bricard G, Ayyoub M, et al. Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunol Immunother 2007; 56: 839-847.
36. Zhong XY, Zhang LH, Jia SQ, Shi T, Niu ZJ, Du H, et al. Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer. Histopathology 2008; 52: 560-568.
37. He Q, Chen J, Lin HL, Hu PJ, Chen MH. Expression of peroxisome proliferator-activated receptor gamma, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases. Chin Med J 2007; 120: 1498-1504.
38. Kubota E, Kataoka H, Aoyama M, Mizoshita T, Mori Y, Shimura T, et al. Role of ES cell-expressed Ras (ERas) in tumorigenicity of gastric cancer. Am J Pathol 2010; 177: 955-963.
39. Ougolkov A, Yamashita K, Bilim V, Takahashi Y, Mai M, Minamoto T. Abnormal expression of E-cadherin, beta-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis. Int J Colorectal Dis 2003; 18: 160-166.
40. Matsukawa Y, Semba S, Kato H, Koma Y, Yanagihara K, Yokozaki H. Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo. Pathobiology 2010; 77: 155-162.
41. Huang Y, Yang M, Yang H, Zeng Z. Upregulation of the GRIM-19 gene suppresses invasion and metastasis of human gastric cancer SGC-7901 cell line. Exp Cell Res 2010; 316: 2061-2070.
42. Ando K, Kakeji Y, Kitao H, Iimori M, Zhao Y, Yoshida R, et al. High expression of BUBR1 is one of the factors for inducing DNA aneuploidy and progression in gastric cancer. Cancer Sci 2010; 101: 639-645.
43. Chang W, Ma L, Lin L, Gu L, Liu X, Cai H, et al. Identification of novel hub genes associated with liver metastasis of gastric cancer. Int J Cancer 2009; 125: 2844-2853.
44. Steeg PS, Horak CE, Miller KD. Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res 2008; 14: 5006-5012.
45. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 2007; 56: 782-789.
46. Guan-Zhen Y, Ying C, Can-Rong N, Guo-Dong W, Jian-Xin Q, Jie-Jun W. Reduced protein expression of metastasis-related genes (nm23, KISS1, KAI1 and p53) in lymph node and liver metastases of gastric cancer. Int J Exp Pathol 2007; 88: 175-183.
47. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002; 224: 748-756.
48. R, Della Pina C, Crocetti L, Bozzi E, Cioni D. Clinical management of focal liver lesions: the key role of real-time contrast-enhanced US. Eur Radiol 2007; 17 Suppl 6: F73-F79.
49. Hosten N, Puls R, Bechstein WO, Felix R. Focal liver lesions: Doppler ultrasound. Eur Radiol 1999; 9: 428-435.
50. Quaia E, D'Onofrio M, Palumbo A, Rossi S, Bruni S, Cova M. Comparison of contrast-enhanced ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver: diagnostic performance and confidence. Eur Radiol 2006; 16: 1599-1609.
51. Bartolotta TV, Taibbi A, Midiri M, Lagalla R. Focal liver lesions: contrast-enhanced ultrasound. Abdom Imaging 2009; 34: 193-209.
52. Cokkinos D, Blomley M, Harvey C, Lim A, Cunningham C, Cosgrove D. Can contrast-enhanced ultrasonography characterize focal liver lesions and differentiate between benign and malignant, thus providing a one-stop imaging service for patients? J Ultrasound 2007; 10: 186-193.
53. Lim JS, Yun MJ, Kim MJ, Hyung WJ, Park MS, Choi JY, et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics 2006; 26: 143-156.
54. Pan Z, Zhang H, Yan C, Du L, Ding B, Song Q, et al. Determining gastric cancer resectability by dynamic MDCT. Eur Radiol 2010; 20: 613-620.
55. Ward J, Robinson PJ, Guthrie JA, Downing S, Wilson D, Lodge JP, et al. Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology 2005; 237: 170-180.
56. Meijerink MR, van Waesberghe JH, van der Weide L, van den Tol P, Meijer S, van Kuijk C. Total-liver-volume perfusion CT using 3-D image fusion to improve detection and characterization of liver metastases. Eur Radiol 2008; 18: 2345-2354.
57. SM, Semelka RC. Hepatic imaging: comparison of modalities. Radiol Clin North Am 2005; 43: 929-947, ix.
58. Liu PS, Francis IR. Hepatic imaging for metastatic disease. Cancer J 2010; 16: 93-102.
59. Bruegel M, Rummeny EJ. Hepatic metastases: use of diffusion-weighted echo-planar imaging. Abdom Imaging 2010; 35: 454-461.
60. Ba-Ssalamah A, Uffmann M, Saini S, Bastati N, Herold C, Schima W. Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol 2009; 19: 342-357.
61. Nasu K, Kuroki Y, Nawano S, Kuroki S, Tsukamoto T, Yamamoto S, et al. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006; 239: 122-130.
62. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008; 248: 894-900.
63. Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med 2003; 44: 690-699.
64. Donati OF, Hany TF, Reiner CS, von Schulthess GK, Marincek B, Seifert B, et al. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med 2010; 51: 692-699.
65. Dassen AE, Lips DJ, Hoekstra CJ, Pruijt JF, Bosscha K. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol 2009; 35: 449-455.
66. Khandani AH, Calvo BF, O'Neil BH, Jorgenson J, Mauro MA. A pilot study of early 18F-FDG PET to evaluate the effectiveness of radiofrequency ablation of liver metastases. Am J Roentgenol 2007; 189: 1199-1202.
67. Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS, et al. Follow-up study of peripheral blood carcinoembryonic antigen mRNA using reverse transcription-polymerase chain reaction as an early marker of clinical recurrence in patients with curatively resected gastric cancer. Am J Clin Oncol 2005; 28: 24-29.
68. Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther 2008; 25: 1075-1084.
69. Kwok CM, Wu CW, Lo SS, Shen KH, Hsieh MC, Lui WY. Survival of gastric cancer with concomitant liver metastases. Hepatogastroenterology 2004; 51: 1527-1530.
70. Ishigami S, Natsugoe S, Nakashima H, Tokuda K, Nakajo A, Okumura H, et al. Biological aggressiveness of alpha-fetoprotein (AFP)-positive gastric cancer. Hepatogastroenterology 2006; 53: 338-341.
71. Yokoyama H, Ikehara Y, Kodera Y, Ikehara S, Yatabe Y, Mochizuki Y, et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer 2006; 95: 1504-1513.
72. Ushiku T, Shinozaki A, Shibahara J, Iwasaki Y, Tateishi Y, Funata N, et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol 2010; 34: 533-540.
73. Leong T. Chemotherapy and radiotherapy in the management of gastric cancer. Curr Opin Gastroenterol 2005; 21: 673-678.
74. JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005; 10 Suppl 3: S49-S58.
75. Saidi RF, ReMine SG, Dudrick PS, Hanna NN. Is there a role for palliative gastrectomy in patients with stage IV gastric cancer? World J Surg 2006; 30: 21-27.
76. Pollock RE, Roth JA. Cancer-induced immunosuppression: implications for therapy? Semin Surg Oncol 1989; 5: 414-419.
77. McCarter MD, Fong Y. Role for surgical cytoreduction in multimodality treatments for cancer. Ann Surg Oncol 2001; 8: 38-43.
78. Doglietto GB, Pacelli F, Caprino P, Alfieri S, Carriero C, Malerba M, et al. Palliative surgery for far-advanced gastric cancer: a retrospective study on 305 consecutive patients. Am Surg 1999; 65: 352-355.
79. Fujisaki S, Tomita R, Nezu T, Kimizuka K, Park E, Fukuzawa M. Prognostic studies on gastric cancer with concomitant liver metastases. Hepatogastroenterology 2001; 48: 892-894.
80. Miyagaki H, Fujitani K, Tsujinaka T, Hirao M, Yasui M, Kashiwazaki M, et al. The significance of gastrectomy in advanced gastric cancer patients with non-curative factors. Anticancer Res 2008; 28: 2379-2384.
81. Kunisaki C, Makino H, Takagawa R, Oshima T, Nagano Y, Fujii S, et al. Impact of palliative gastrectomy in patients with incurable advanced gastric cancer. Anticancer Res 2008; 28: 1309-1315.
82. Lin SZ, Tong HF, You T, Yu YJ, Wu WJ, Chen C, et al. Palliative gastrectomy and chemotherapy for stage IV gastric cancer. J Cancer Res Clin Oncol 2008; 134: 187-192.
83. Kim DY, Joo JK, Park YK, Ryu SY, Kim YJ, Kim SK, et al. Is palliative resection necessary for gastric carcinoma patients? Langenbecks Arch Surg 2008; 393: 31-35.
84. Hartgrink HH, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJ. Value of palliative resection in gastric cancer. Br J Surg 2002; 89: 1438-1443.
85. Fujitani K, Yang HK, Kurokawa Y, Park do J, Tsujinaka T, Park BJ, et al. Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol 2008; 38: 504-506.
86. Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, et al. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery 2003; 133: 507-511.
87. Morise Z, Sugioka A, Hoshimoto S, Kato T, Ikeda M, Uyama I, et al. The role of hepatectomy for patients with liver metastases of gastric cancer. Hepatogastroenterology 2008; 55: 1238-1241.
88. Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002; 235: 86-91.
89. Shirabe K, Wakiyama S, Gion T, Watanabe M, Miyazaki M, Yoshinaga K, et al. Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literature. HPB (Oxford) 2006; 8: 89-92.
90. Tsujimoto H, Ichikura T, Ono S, Sugasawa H, Hiraki S, Sakamoto N, et al. Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer. Hepatol Int 2010; 4: 406-413.
91. Shirabe K, Shimada M, Matsumata T, Higashi H, Yakeishi Y, Wakiyama S, et al. Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection: a multi-institutional study of the indications for resection. Hepatogastroenterology 2003; 50: 1560-1563.
92. Kerkar SP, Kemp CD, Duffy A, Kammula US, Schrump DS, Kwong KF, et al. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials 2009; 10: 121.
93. Mayo SC, Pawlik TM. Thermal ablative therapies for secondary hepatic malignancies. Cancer J 2010; 16: 111-117.
94. An JY, Kim JY, Choi MG, Noh JH, Choi D, Sohn TS, et al. Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma. Yonsei Med J 2008; 49: 1046-1051.
95. Shiomi H, Naka S, Sato K, Demura K, Murakami K, Shimizu T, et al. Thoracoscopy-assisted magnetic resonance guided microwave coagulation therapy for hepatic tumors. Am J Surg 2008; 195: 854-860.
96. Kim HR, Ha Cheon S, Lee KH, Ryun Ahn J, Jeung HC, Sook Lee S, et al. Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. Int J Hyperthermia 2010; 26: 305-315.
97. Kim HO, Hwang SI, Hong HP, Yoo CH. Radiofrequency ablation for metachronous hepatic metastases from gastric cancer. Surg Laparosc Endosc Percutan Tech 2009; 19: 208-212.
98. Iannitti DA, Dupuy DE, Mayo-Smith WW, Murphy B. Hepatic radiofrequency ablation. Arch Surg 2002; 137: 422-426.
99. Chen MH, Yang W, Yan K, Gao W, Dai Y, Wang YB, et al. Treatment efficacy of radiofrequency ablation of 338 patients with hepatic malignant tumor and the relevant complications. World J Gastroenterol 2005; 11: 6395-6401.
100. Shi J, Li J, Liu JD, Li ZX. The therapeutic effects of radiofrequency ablation for metastatic liver cancer. J Abdom Surg (Chin) 2007; 20: 150-152.
101. Boutros C, Somasundar P, Garrean S, Saied A, Espat NJ. Microwave coagulation therapy for hepatic tumors: review of the literature and critical analysis. Surg Oncol 2010; 19: e22-e32.
102. Yu J, Liang P, Yu X, Liu F, Chen L, Wang Y. A comparison of microwave ablation and bipolar radiofrequency ablation both with an internally cooled probe: Results in ex vivo and in vivo porcine livers. Eur J Radiol 2010; Epub ahead of print.
103. Liang P, Dong BW, Yu XL, Yu DJ, Feng L, Gao YY, et al. Evaluation of long-term therapeutic effects of ultrasound-guided percutaneous microwave ablation of liver metastases. Natil Med J China (Chin) 2006; 86: 806-810.
104. Ganeshan A, Upponi S, Hon LQ, Warakaulle D, Uberoi R. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol 2008; 19: 847-851.
105. Hirasawa T, Asahara S, Fujisaki S, Kuraoka K, Takano K, Kamei A, et al. Transcatheter arterial chemoembolization (TACE) using degradable starch microspheres (DSM) for metastatic liver tumors in patients with gastric cancer. Nippon Shokakibyo Gakkai Zasshi 2008; 105: 367-372.
106. Ojima H, Ootake S, Yokobori T, Mochida Y, Hosouchi Y, Nishida Y, et al. Treatment of multiple liver metastasis from gastric carcinoma. World J Surg Oncol 2007; 5: 70.
107. Yamakado K, Nakatsuka A, Takaki H, Mori Y, Tonouchi H, Kusunoki M, et al. Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer. J Vasc Interv Radiol 2005; 16: 1747-1751.
108. Yan D, Li H, Wei WQ, Liu DZ, Zeng HY, Yang LX. Evaluation of efficacy and influence factors of transarterial interventional therapy in patients with liver metastasis from malignancy of alimentary tract. Chin J Oncol (Chin) 2007; 29: 867-870.
109. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063-1069.
110. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
111. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28: 1547-1553.
112. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006; 12: 3402-3407.
113. Fujii M. Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol 2008; 13: 201-205.
114. Li ZY, Tang L, Zhang LH, Bu ZD, Wu AW, Wu XJ, et al. Weekly docetaxel and cisplatin plus fluorouracil as a preoperative treatment for gastric cancer patients with synchronous multiple hepatic metastases: a pilot study. Med Oncol 2010; 27: 1314-1318.
115. Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, Okubo S, et al. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 2010; 66: 721-728.
116. Kochi M, Fujii M, Kanamori N, Kaiga T, Okubo R, Hagiwara K, et al. Irinotecan plus S-1 for liver metastases of gastric cancer. Hepatogastroenterology 2009; 56: 1755-1759.